The role of a new druggable protein and its interacting partners in blood development and blood diseases

一种新的药物蛋白及其相互作用伙伴在血液发育和血液疾病中的作用

• 批准号: nhmrc : GNT1070687
• 负责人: Dr M. Cristina Keightley
• 金额: $ 56.76万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/role-new-druggable-blood-diseases/1344993
• 关键词: role; new; druggable; protein; its

Zbtb11 is a druggable protein that is mis-expressed in blood cancers - second biggest cause of cancer death in Australia - and liver cancer, third leading cause of death from cancer worldwide. We have found that it interacts with 2 other proteins with potential roles in these diseases. Our studies examine the nature of these Zbtb11-partner interactions and their particular consequences for blood disorders. Zbtb11 contributions to disease development will be a target for novel disease therapy.

Zbtb 11是一种可药用蛋白质，在血癌（澳大利亚癌症死亡的第二大原因）和肝癌（全球癌症死亡的第三大原因）中错误表达。我们发现它与其他2种在这些疾病中具有潜在作用的蛋白质相互作用。我们的研究检查了这些Zbtb 11-伴侣相互作用的性质及其对血液疾病的特定后果。zbtb 11对疾病发展的贡献将成为新疾病治疗的靶点。